- Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration - - FDA agrees on UMSARS Part I ...
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I ...
MELBOURNE, Australia and SAN FRANCISCO, June 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, trading under the ASX code ATHDA until 12 June; NASDAQ: ATHE) ("Alterity" or "the Company"), ...
The regulator ticks off on key elements of a phase III trial, including study population, endpoint selection, dosing regimen and treatment duration Alterity’s Multiple System Atrophy (MSA) candidate ...
Earlier this spring, AMD, Broadcom, Meta Platforms, Microsoft, Nvidia, and OpenAI formed the Optical Compute Interconnect ...
The planets remained in these positions for several weeks. However, January 21 offered the cleanest viewing window. The Moon rose late that evening, leaving the sky completely dark. This lack of ...
This review provides an overview of artificial intelligence–enabled biological models, focusing on their applications in designing biological molecules and systems. We review foundation models that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results